The present invention provides an oral formulation of arsenic trioxide (As.sub.2O.sub.3) for the treatment of a variety of hematological malignancies, including acute myeloid leukemia (AML) and acute promyelocytic leukemia (APL). The present invention also provides methods for making the oral arsenic trioxide formulation. Methods of using the oral arsenic trioxide formulation are also described.
This application claims priority benefit to U.S. provisional application No. 60/417,200, filed Oct. 9, 2002; and U.S. provisional application No. 60/483,014, filed Jun. 25, 2003, each of which is incorporated herein by reference in its entirety.
